Responsiveness to changes within subjects and differences in changes between salmeterol + ipratropium bromide (n = 45), salmeterol + placebo (n = 43), and placebo + placebo (n = 45)
| Change in quality of life | p value6-151(overall) | ||||
|---|---|---|---|---|---|
| Salmeterol+ ipratropium bromide | Salmeterol + placebo | Placebo+ placebo | |||
| SGRQ | –2.4 (11.0) | –0.01 (7.1) | +0.5 (9.2) | 0.232 | |
| Symptoms | –8.1 (15.3)6-160 | +1.4 (16.3) | +0.7 (20.0) | 0.019 | |
| Activities | –2.6 (14.5) | +0.5 (8.1) | +1.2 (10.9) | 0.227 | |
| Impact | –0.5 (12.1) | –0.5 (10.9) | –0.1 (13.3) | 0.944 | |
| CRQ | 0.19 (0.6)6-150 | –0.21 (0.8) | <0.01 (0.7) | 0.036 | |
| Dyspnoea | 0.21 (0.8) | –0.08 (0.9) | 0.07 (1.0) | 0.368 | |
| Fatigue | 0.25 (0.8)6-150 | –0.13 (0.9) | <0.01 (0.9) | 0.085 | |
| Emotions | 0.17 (0.8) | –0.34 (0.9)6-150 | 0.04 (0.8) | 0.009 | |
| Mastery | 0.17 (0.8) | –0.20 (1.0) | <0.01 (0.7) | 0.130 | |
SGRQ = St George’s Respiratory Questionnaire; CRQ = Chronic Respiratory Disease Questionnaire.
↵6-151 Covariance analysis on change scores with treatment groups as a factor and baseline score as a covariate. Improvement is indicated by a minus for the SGRQ and a plus for the CRQ.
Within-patient changes:
↵6-150 p<0.05;
↵6-160 p<0.001.